公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2013 | Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: A multicentre study | Dai C.-Y.; TAI-CHUNG TSENG ; Wong G.L.H.; Huang J-F.; Wong V.W.S.; CHUN-JEN LIU ; Yu M.-L.; Chuang W.-L.; JIA-HORNG KAO ; Yuen Chan H.L.; DING-SHINN CHEN | Journal of Antimicrobial Chemotherapy | 20 | 19 | |
2020 | Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action. Authors' reply | Estes C.; Chan H.L.Y.; Chien R.N.; Chuang W.-L.; Fung J.; Goh G.B.-B.; Hu T.H.; Huang J.-F.; Jang B.K.; Jun D.W.; JIA-HORNG KAO ; Lee J.-W.; Lin H.-C.; Razavi-Shearer K.; Seto W.-K.; Wong G.L.H.; Wong V.W.S.; Razavi H. | Alimentary Pharmacology and Therapeutics | 1 | 0 | |
2020 | Modelling NAFLD disease burden in four Asian regions—2019-2030 | Estes C.; Chan H.L.Y.; Chien R.N.; Chuang W.-L.; Fung J.; Goh G.B.-B.; Hu T.H.; Huang J.-F.; Jang B.K.; Jun D.W.; JIA-HORNG KAO ; Lee J.-W.; Lin H.-C.; Razavi-Shearer K.; Seto W.-K.; Wong G.L.H.; Wong V.W.S.; Razavi H. | Alimentary Pharmacology and Therapeutics | 87 | 76 | |
2022 | Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine | Park J.; Le A.K.; TAI-CHUNG TSENG ; Yeh M.-L.; Jun D.W.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung K.S.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO ; Yang H.-I.; Nguyen M.H. | Clinical Gastroenterology and Hepatology | 3 | 4 | |
2021 | Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients | Liu M.; TAI-CHUNG TSENG ; Jun D.W.; Yeh M.-L.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung M.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO ; Yang H.-I.; Nguyen M.H. | Hepatology International | 14 | 14 | |
2020 | Use of glecaprevir/pibrentasvir in patients with chronic hepatitis c virus infection and severe renal impairment | Yap D.Y.H.; Liu K.S.H.; Hsu Y.-C.; Wong G.L.H.; Tsai M.-C.; CHIEN-HUNG CHEN ; Hsu C.-S.; Hui Y.T.; Li M.K.K.; CHEN-HUA LIU ; Kan Y.-M.; Yu M.-L.; Yuen M.-F. | Clinical and Molecular Hepatology | 7 | 8 |